We investigate the brain networks and neurotransmitters involved in symptoms of movement disorders, such as Parkinson's disease, and the mechanisms by which modulating these networks through electrical stimulation affects these symptoms. We are particularly interested in the mechanisms through which neuromodulation therapies like deep brain stimulation affect non-motor brain functions, such as cognitive function and mood. We use imaging of specific neurotransmitters, such as acetylcholine and dopamine, to understand the changes in brain chemistry associated with the clinical effects of deep brain stimulation and to predict which patients are likely to have changes in non-motor symptoms following DBS. Through collaborations with our neurosurgery colleagues, we explore brain function by making recordings during DBS surgery during motor and non-motor tasks. Dr. Mills collaborates with researchers in the Department of Neurosurgery, the Division of Geriatric and Neuropsychiatry in the Department of Psychiatry and Behavioral Sciences and in the Division of Nuclear Medicine within the Department of Radiology to translate neuroimaging and neurophysiology findings into clinical applications.

How do brain dynamics give rise to our sensory experience of the world? The O'Connor lab works to answer this question by taking advantage of the fact that key architectural features of the mammalian brain are similar across species. This allows us to leverage the power of mouse genetics to monitor and manipulate genetically and functionally defined brain circuits during perception. We train mice to perform simple perceptual tasks. By using quantitative behavior, optogenetic and chemical-genetic gain- and loss-of-function perturbations, in vivo two-photon imaging, and electrophysiology, we assemble a description of the relationship between neural circuit function and perception. We work in the mouse tactile system to capitalize on an accessible mammalian circuit with a precise mapping between the sensory periphery and multiple brain areas. Our mission is to reveal the neural circuit foundations of sensory perception; to provide a framework to understand how circuit dysfunction causes mental and behavioral aspects of neuropsychiatric illness; and to help others fulfill creative potential and contribute to human knowledge.

The Mollie Meffert Lab studies mechanisms underlying enduring changes in brain function. We are interested in understanding how programs of gene expression are coordinated and maintained to produce changes in synaptic, neuronal and cognitive function. Rather than concentrating on single genes, our research is particularly focused on understanding the upstream processes that allow neuronal stimuli to synchronously orchestrate both up and down-regulation of the many genes required to mediate changes in growth and excitation. This process of gene target specificity is implicit to the appropriate production of gene expression programs that control lasting alterations in brain function.

The Marshall Shuler Laboratory aims to understand the means by which brain reward systems convey reward value, expectancy, quality, probability and utility, and the rules by which such activity is used to affect synaptic weight within brain networks to encode stimulus-action associations. We use an interdisciplinary approach combining multisite recordings of neural activity, targeted pharmacological manipulation, viral-mediated gene transfer and behavior to study the neural mechanisms of reward-based interval learning in the primary visual cortex.

The Sujatha Kannan Lab works to develop therapeutic strategies for preventing perinatal brain injuries from occurring during development. We use a unique combination of nanotechnology, animal model development and in vivo imaging to better understand the mechanism and progression of cellular and metabolic conditions that lead to perinatal brain injury, with a focus on autism and cerebral palsy.

The Systems neurobiology Laboratory is a group of laboratories that all study various aspects of neurobiology. These laboratories include: (1) computational neurobiology Laboratory: The goal of their research is to build bridges between brain levels from the biophysical properties of synapses to the function of neural systems. (2) computational Principles of Natural Sensory Processing: Research in this lab focuses on the computational principles of how the brain processes information. (3) Laboratory for Cognitive neuroscience: This laboratory studies the neural and genetic underpinnings of language and cognition. (4) Sloan-Swartz Center for Theoretical neurobiology: The goal of this laboratory is develop a theoretical infrastructure for modern experimental neurobiology. (5) Organization and development of visual cortex: This laboratory is studying the organization and function of neural circuits in the visual cortex to understand how specific neural components enable visual perception and to elucidate the basic neural mechanisms that underlie cortical function. (6) Neural mechanism of selective visual attention: This laboratory studies the neural mechanisms of selective visual attention at the level of the individual neuron and cortical circuit, and relates these findings to perception and conscious awareness. (7) Neural basis of vision: This laboratory studies how sensory signals in the brain become integrated to form neuronal representation of the objects that people see.

Research in the John Ulatowski Lab explores the regulatory mechanisms of oxygen delivery to the brain and cerebral blood flow. Our work includes developing and applying new techniques and therapies for stroke as well as non-invasive techniques for monitoring brain function, fluid management and sedation in brain injury patients. We also examine the use of novel oxygen carriers in blood. We’ve recently begun exploring new methods for perioperative and periprocedural care that would help to optimize patient safety in the future.

Dr. Hua's research has centered on the development of novel MRI technologies for in vivo functional and physiological imaging in the brain, and the application of such methods for studies in healthy and diseased brains. These include the development of human and animal MRI methods to measure functional brain activities, cerebral perfusion and oxygen metabolism at high (3 Tesla) and ultra-high (7 Tesla and above) magnetic fields. He is particularly interested in novel MRI approaches to image small blood and lymphatic vessels in the brain. Collaborating with clinical investigators, these techniques have been applied 1) to detect functional, vascular and metabolic abnormalities in the brain in neurodegenerative diseases such as Huntingdon's disease (HD), Parkinson's disease (PD), Alzheimer's disease (AD) and mental disorders such as schizophrenia; and 2) to map brain functions and cerebrovascular reactivity for presurgical planning in patients with vascular malformations, brain tumors and epilepsy.

Dr. Zhou's research focuses on developing new in vivo MRI and MRS methodologies to study brain function and disease. His most recent work includes absolute quantification of cerebral blood flow, quantification of functional MRI, high-resolution diffusion tensor imaging (DTI), magnetization transfer mechanism, development of chemical exchange saturation transfer (CEST) technology, brain pH MR imaging, and tissue protein MR imaging. Notably, Dr. Zhou and his colleagues invented the amide proton transfer (APT) approach for brain pH imaging and tumor protein imaging. His initial paper on brain pH imaging was published in Nature Medicine in 2003 and his most recent paper on tumor treatment effects was published in Nature Medicine in 2011. A major part of his current research is the pre-clinical and clinical imaging of brain tumors, strokes, and other neurologic disorders using the APT and other novel MRI techniques. The overall goal is to achieve the MRI contrast at the protein and peptide level without injection of exogenous agents and improve the diagnostic capability of MRI and the patient outcomes.

Chordoma research is led by a comprehensive team including Gary Gallia, M.D., director of the Neurosurgery Skull Base Tumor Center. The laboratory focuses on developing new therapies for brain and skull base tumors, and has established the first primary skull base chordoma xenograft mouse model. The team is also exploring high throughput drug screening using the chordoma model, and the molecular pathways responsible for tumor maintenance and growth.